Pfizer is increasingly seen as a deep value opportunity, with shares trading around $26 and a forward P/E of roughly 8.8x, a steep discount to peers like Merck and Johnson & Johnson. The stock has fallen nearly 60% from pandemic highs amid post-COVID revenue normalization and looming patent expirations for key drugs such as Eliquis and Ibrance. However, bulls point to the $43 billion Seagen acquisition strengthening Pfizer's oncology pipeline, a GLP-1 portfolio with late-stage oral candidates, and a catalyst-rich 2026 featuring over 20 Phase 3 trials. A dividend yield of approximately 6.5%, backed by 17 consecutive years of increases, provides an income buffer while awaiting a potential re-rating that could double the stock over the next three to five years.
Pfizer IncArticle presents Pfizer as a deep value opportunity with potential 2x upside, citing low P/E, Seagen acquisition, GLP-1 pipeline, and dividend yield.
Johnson & Johnson
Merck & Company Inc
Merck KGaA